FILE PHOTO: Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel, Switzerland, March 29, 2018. REUTERS/Arnd Wiegmann/File Photo
ZURICH (Reuters) – Novartis has 25 potential blockbuster treatments in development, the company said ahead of a management event in the United States on Thursday.
“Our pipeline is industry-leading with more than 25 potential blockbusters and this pace of innovation positions Novartis well for the future”, said Novartis Chief Executive Vas Narasimhan in a statement.
Reporting by Silke Koltrowitz